These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 19726410)

  • 21. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
    Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
    Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease.
    Ben Sassi S; Nabli F; Hentati E; Nahdi H; Trabelsi M; Ben Ayed H; Amouri R; Duda JE; Farrer MJ; Hentati F
    Parkinsonism Relat Disord; 2012 Mar; 18(3):243-6. PubMed ID: 22056842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease.
    Choi JM; Woo MS; Ma HI; Kang SY; Sung YH; Yong SW; Chung SJ; Kim JS; Shin HW; Lyoo CH; Lee PH; Baik JS; Kim SJ; Park MY; Sohn YH; Kim JH; Kim JW; Lee MS; Lee MC; Kim DH; Kim YJ
    Neurogenetics; 2008 Oct; 9(4):263-9. PubMed ID: 18704525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.
    Brockmann K; Gröger A; Di Santo A; Liepelt I; Schulte C; Klose U; Maetzler W; Hauser AK; Hilker R; Gomez-Mancilla B; Berg D; Gasser T
    Mov Disord; 2011 Nov; 26(13):2335-42. PubMed ID: 21989859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
    Seol W
    BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants.
    Zhang L; Quadri M; Guedes LC; Coelho M; Valadas A; Mestre T; Lobo PP; Rosa MM; Simons E; Oostra BA; Ferreira JJ; Bonifati V
    Parkinsonism Relat Disord; 2013 Oct; 19(10):897-900. PubMed ID: 23726462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PINK1 mutations in a Brazilian cohort of early-onset Parkinson's disease patients.
    Godeiro-Junior C; de Carvalho-Aguiar PM; Felício AC; Barsottini OG; Silva SM; Borges V; Andrade LA; Ferraz HB
    Mov Disord; 2009 Aug; 24(11):1693-6. PubMed ID: 19562775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal.
    Ferreira JJ; Guedes LC; Rosa MM; Coelho M; van Doeselaar M; Schweiger D; Di Fonzo A; Oostra BA; Sampaio C; Bonifati V
    Mov Disord; 2007 Jun; 22(8):1194-201. PubMed ID: 17469194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
    Gaig C; Ezquerra M; Marti MJ; Muñoz E; Valldeoriola F; Tolosa E
    Arch Neurol; 2006 Mar; 63(3):377-82. PubMed ID: 16533964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical molecular genetics for PARK8 (LRRK2)].
    Tomiyama H; Hatano T; Hattori N
    Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From genes to proteins in mendelian Parkinson's disease: an overview.
    Pirkevi C; Lesage S; Brice A; Başak AN
    Anat Rec (Hoboken); 2009 Dec; 292(12):1893-901. PubMed ID: 19943343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.
    Mirelman A; Heman T; Yasinovsky K; Thaler A; Gurevich T; Marder K; Bressman S; Bar-Shira A; Orr-Urtreger A; Giladi N; Hausdorff JM;
    Mov Disord; 2013 Oct; 28(12):1683-90. PubMed ID: 24123150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism.
    Trinh J; Amouri R; Duda JE; Morley JF; Read M; Donald A; Vilariño-Güell C; Thompson C; Szu Tu C; Gustavsson EK; Ben Sassi S; Hentati E; Zouari M; Farhat E; Nabli F; Hentati F; Farrer MJ
    Neurobiol Aging; 2014 May; 35(5):1125-31. PubMed ID: 24355527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
    Marras C; Alcalay RN; Caspell-Garcia C; Coffey C; Chan P; Duda JE; Facheris MF; Fernández-Santiago R; Ruíz-Martínez J; Mestre T; Saunders-Pullman R; Pont-Sunyer C; Tolosa E; Waro B;
    Mov Disord; 2016 Aug; 31(8):1192-202. PubMed ID: 27091104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on the genetics of Parkinson's disease.
    Gasser T
    Mov Disord; 2007 Sep; 22 Suppl 17():S343-50. PubMed ID: 18175395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.
    Lesage S; Janin S; Lohmann E; Leutenegger AL; Leclere L; Viallet F; Pollak P; Durif F; Thobois S; Layet V; Vidailhet M; Agid Y; Dürr A; Brice A; ; Bonnet AM; Borg M; Broussolle E; Damier P; Destée A; Martinez M; Penet C; Rasco O; Tison F; Tranchan C; Vérin M
    Arch Neurol; 2007 Mar; 64(3):425-30. PubMed ID: 17353388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson's disease.
    Quattrone A; Bagnato A; Annesi G; Novellino F; Morgante L; Savettieri G; Zappia M; Tarantino P; Candiano IC; Annesi F; Civitelli D; Rocca FE; D'Amelio M; Nicoletti G; Morelli M; Petrone A; Loizzo P; Condino F
    Mov Disord; 2008 Jan; 23(1):21-7. PubMed ID: 17975812
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical implications of gene discovery in Parkinson's disease and parkinsonism.
    Wider C; Foroud T; Wszolek ZK
    Mov Disord; 2010; 25 Suppl 1():S15-20. PubMed ID: 20187245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of Leucine-rich repeat kinase 2 (LRRK2) and Parkinson protein 2 (parkin, PARK2) genes mutations in Slovak Parkinson disease patients.
    Bognar C; Baldovic M; Benetin J; Kadasi L; Zatkova A
    Gen Physiol Biophys; 2013 Mar; 32(1):55-66. PubMed ID: 23531835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic screening for the LRRK2 R1441C and G2019S mutations in Parkinsonian patients from Campania.
    De Rosa A; De Michele G; Guacci A; Carbone R; Lieto M; Peluso S; Picillo M; Barone P; Salemi F; Laiso A; Saccà F; Tessitore A; Pellecchia MT; Bonifati V; Criscuolo C
    J Parkinsons Dis; 2014; 4(1):123-8. PubMed ID: 24496098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.